ProNAi Therapeutics (DNAI) Posts Wider Q2 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to ProNAi Therapeutics (DNAI) Posts Wider Q2 Loss

ProNAi Therapeutics Reports Second Quarter 2015 Results

August 21, 2015 7:00 AM EDT

Completed Upsized Initial Public Offering, Raising Gross Proceeds of $158.4 MillionAdvanced Clinical Programs for PNT2258 in DLBCL and Richter's Transformed CLLStrengthened Management Team and Board of Directors

VANCOUVER, Aug. 21, 2015 /CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today reported its financial and operational results for the second quarter of 2015.

"During the second quarter we continued to advance our clinical programs for PNT2258, opening clinical trial sites and enrolling patients into our Phase 2... More